Company profile
Delota Corp.
OTC: SYDRF · Healthcare · Medical - Pharmaceuticals
Canadian filerHQ Concord, ONReports USD
#508 of 1,422 Healthcare companies by revenue61st-percentile growth
EA Score
——FH —DQ —GM —SS 40
v0.1 · 5/100 weight · pillars only
↑ return on equity, return on assets · ↓ growth stability, listing tenure
Methodology →Revenue TTM
$25.2M
Rev growth YoY (TTM)
-0.1%
Net income (FY)
$407.6k
Employees
140
as of 2026-08-24
Market cap
$2.9M
as of 2026-08-24
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$29.2M40.2M CAD2025
Net income$407.6k561.8k CAD2025
Operating income$349.7k482.0k CAD2025
Total assets$10.2M14.8M CAD2025
Liabilities$9.4M13.6M CAD2025
Equity$819.1k1.2M CAD2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Delota Corp.’s revenue?
Delota Corp. booked $29.2M in FY2025 revenue, growing 16% year over year — faster than most Healthcare companies we track, at a 1.4% net margin.
Peers · Healthcare
YourWay Cannabis Brands Inc.——Synergy CHC Corp.35DScilex Holding Company28DIMRIS Inc.——Nanalysis Scientific Corp.59COscar Health, Inc.50DKey facts
CEORobert Cameron-Takehiko Wickham
SectorHealthcare
IndustryMedical - Pharmaceuticals
HeadquartersConcord, ON
ExchangeOTC: SYDRF
Employees140
IPO date2021-10-27
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.